Fresenius Kabi Oncology, a New Delhi based multinational company with sales over Rs.470 crore, has posted better growth in net profit during the first quarter ended June 2012 on account of foreign exchange gain. Its net profit increased by 31.6 per cent to Rs.13.04 crore from Rs.9.91 crore in the corresponding period of last year. However, its EBDITA declined by 2.1 per cent to Rs.22.81 crore from Rs.23.30 crore. The company's net sales moved up by 10.5 per cent to Rs.124.06 crore from Rs.112.27 crore. Foreign exchange gain was at Rs.2.89 crore during the quarter.

The formulation sales improved by 19 per cent to Rs.114.66 crore during the first quarter ended June 2012 from Rs.96.37 crore in the same period of last year and its sales of bulk drugs increased by 77.3 per cent to Rs.60.85 crore from Rs.34.31 crore.